Available at pharmacies nationwide — help eligible patients access a copay offer
AZSTARYS is the FIRST and ONLY
d‑MPH
with novel SDX prodrug
and IR activity1,2
aFollowing a single dose of AZSTARYS in healthy adults under fasted conditions.
Mean plasma concentrations continued to gradually decline through 72 hours post dose.1
Select a profile
Name: Sean
Age: 25 years
Sex: Male
Current treatment: MPH ER stimulant
Name: Sarah
Age: 42 years
Sex: Female
Current treatment: None
Source: IQVIA XPD prescriber dynamics data 7/1/2021 through 4/8/2022.
Trademarks and copyrights belong to their respective owners.
ADHD, Attention Deficit Hyperactivity Disorder; AMP, amphetamine; d-MPH, dexmethylphenidate; ER, extended-release; HCl, hydrochloride; IR, Immediate-release;
MPH, methylphenidate; PK, pharmacokinetics; SDX, serdexmethylphenidate.
References: 1. AZSTARYS. Prescribing information. Corium LLC; 2021. 2. Mickle T, Guenther S, Chi G, inventors; KemPharm, Inc, assignee. Methylphenidate-prodrugs, processes of making and using the same. U.S. patent 10,584,113. March 10, 2020. 3. Childress AC, Komolova M, Sallee FR. An update on the pharmacokinetic considerations in the treatment of ADHD with long-acting methylphenidate and amphetamine formulations. Expert Opin Drug Metab Toxicol. 2019;15(11):937-974. doi:10.1080/17425255.2019.1675636 4. Patrick KS, Radke JL, Raymond JR, et al. Drug regimen individualization for attention-deficit/hyperactivity disorder: guidance for methylphenidate and dexmethylphenidate formulations. Pharmacotherapy. 2019;39(6):677-688. doi:10.1002/phar.2190 5. Data on file. Corium LLC.
AZSTARYS is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.
WARNING: ABUSE, MISUSE, AND ADDICTION
AZSTARYS has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including AZSTARYS, can result in overdose and death and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.
Before prescribing AZSTARYS, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout treatment, reassess each patient’s risk and frequently monitor for signs and symptoms of abuse, misuse, and addiction.
Please click here for Full
Prescribing Information,
including Boxed WARNING.
AZSTARYS is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.
WARNING: ABUSE, MISUSE, AND ADDICTION
AZSTARYS has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including AZSTARYS, can result in overdose and death and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.
Before prescribing AZSTARYS, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout treatment, reassess each patient’s risk and frequently monitor for signs and symptoms of abuse, misuse, and addiction.
The site you're about to enter is intended for US healthcare professionals only.
By selecting OK to continue, you confirm you are a healthcare professional.